How should a buyer evaluate vendors in the Organ-on-a-chip Market?

Ask for the comparative reference dataset, not the brochure. Vendors that can show blinded performance against known clinical outcomes are qualitatively different from those showing pretty images [11]. Read More

What validation burden falls on the customer rather than the vendor?

The customer owns context-of-use validation for their specific compound class. Vendors supply platform performance data; sponsors must still demonstrate fitness for their own decision [13]. Read More

Is buying instruments or outsourcing the better entry into the Organ-on-a-chip Market?

Outsource first. Fee-per-study contracts avoid capital approval and reveal whether the data actually changes internal decisions before you commit to infrastructure. Read More

How do organ chips compare with organoids?

Organoids self-organise and capture tissue architecture; chips add perfusion, mechanical cues, and controlled interfaces. Increasingly, vendors combine both — organoids seeded inside perfused devices [5]. Read More

What drives total cost of ownership in the Organ-on-a-chip Market?

Consumables and cells, not the instrument. Recurring device and media spend typically exceeds the capital outlay within two years of routine operation [14]. Read More

Are data outputs portable between platforms?

Rarely. Proprietary file formats and vendor-specific readouts make cross-platform comparison difficult, which is why standardisation work matters commercially as much as scientifically [13]. Read More

Will regulators outside the United States accept chip-derived evidence?

The European Medicines Agency and Japan's PMDA both engage on non-animal methods through innovation pathways, though neither has issued binding acceptance criteria. Early scientific advice meetings are advisable [8]. Read More

Organ on chip Market (2026 - 2035)

ID: MRFR/HC/7026-HCR 120 Pages Nidhi Mandole Last Updated: September 15, 2026

Organ-on-a-chip Market Research Report: Size, Share, Trend Analysis By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Applications (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) – Forecast to 2035

Organ on chip Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)28.1%

2025 Market SizeUSD 0.37 Billion

2035 Market SizeUSD 4.46 Billion

Key Players

Emulate, Inc.

CN Bio Innovations

MIMETAS

TissUse GmbH

InSphero AG

Hesperos, Inc.

Trends

Regulatory Reform Converts Optional Science into Budgeted Line Items
Attrition Economics Make the Business Case
Public Funding Builds the Validation Infrastructure

Opportunities

Regulatory Qualification as a Commercial Moat
Emerging Market Capacity Build-Out
Data Monetisation and Reference Library Licensing

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Report Takeaways |
1. 2.1 By Organ Type |
2. 2.2 By Application |
3. 2.3 By End User |
4. 2.4 By Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Market Dynamics — Drivers |
1. 4.1 Regulatory Phase-Out of Mandatory Animal Testing |
2. 4.2 Clinical Trial Attrition Economics |
3. 4.3 Public Research Funding for Human-Based Models |
4. 4.4 iPSC Supply Chain Maturation
5 Market Dynamics — Restraints |
1. 5.1 Absence of Harmonised Validation Standards |
2. 5.2 Cost per Data Point versus Legacy Assays |
3. 5.3 Shortage of Trained Operators |
4. 5.4 Vendor Lock-In on Proprietary Consumables
6 Market Opportunity Analysis |
1. 6.1 Regulatory Qualification as a Commercial Moat |
2. 6.2 Emerging Market Capacity Build-Out |
3. 6.3 Data Monetisation and Reference Library Licensing |
4. 6.4 Multi-Organ Coupling for ADME Prediction |
5. 6.5 Chemical and Cosmetics Testing Beyond Pharma |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 United States | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 United Kingdom | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Machine Learning and Predictive Model Integration |
2. 8.2 Service Economics versus Instrument Sales |
3. 8.3 Standardisation and Vendor Consolidation |
4. 8.4 Patient-Specific Chips in Clinical Decision-Making
9 Segmentation Analysis |
1. 9.1 By Organ Type | |
  1. 9.1.1 Liver | |
  2. 9.1.2 Heart | |
  3. 9.1.3 Lung | |
  4. 9.1.4 Kidney | |
  5. 9.1.5 Intestine | |
  6. 9.1.6 Other Organ Types |
2. 9.2 By Application | |
  1. 9.2.1 Drug Discovery and Lead Identification | |
  2. 9.2.2 Toxicology and Safety Assessment | |
  3. 9.2.3 Disease Modelling | |
  4. 9.2.4 Personalized Medicine | |
  5. 9.2.5 Other Applications |
3. 9.3 By End User | |
  1. 9.3.1 Pharmaceutical and Biotechnology Companies | |
  2. 9.3.2 Academic and Research Institutes | |
  3. 9.3.3 Contract Research Organizations | |
  4. 9.3.4 Other End Users
10 Competitive Landscape |
1. 10.1 Market Share Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Emulate, Inc. | |
  2. 10.3.2 CN Bio Innovations | |
  3. 10.3.3 MIMETAS | |
  4. 10.3.4 TissUse GmbH | |
  5. 10.3.5 InSphero AG | |
  6. 10.3.6 Hesperos, Inc. | |
  7. 10.3.7 Nortis, Inc. | |
  8. 10.3.8 AxoSim, Inc. | |
  9. 10.3.9 AlveoliX AG | |
  10. 10.3.10 BiomimX S.r.l. | |
  11. 10.3.11 SynVivo, Inc. | |
  12. 10.3.12 Draper Laboratory
11 Recent Developments & News
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Citations |
3. 12.3 Abbreviations
13 Detailed Sources and Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Organ-on-a-chip Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Organ-on-a-chip Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis – Estimated Contribution to Growth Momentum, 2026–2035 |
TABLE 4 Restraint Impact Analysis – Estimated Drag on Growth Momentum, 2026–2035 |
TABLE 5 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Market Size, by Organ Type, 2021–2035 (USD Billion) |
TABLE 12 Global Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 13 Global Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 14 North America Market Size, by Organ Type and Application, 2021–2035 (USD Billion) |
TABLE 15 Europe Market Size, by Organ Type and Application, 2021–2035 (USD Billion) |
TABLE 16 Asia-Pacific Market Size, by Organ Type and Application, 2021–2035 (USD Billion) |
TABLE 17 South America Market Size, by Organ Type and Application, 2021–2035 (USD Billion) |
TABLE 18 Middle East & Africa Market Size, by Organ Type and Application, 2021–2035 (USD Billion) |
TABLE 19 Competitive Benchmarking Matrix, 2026 |
TABLE 20 Company Profiles – Key Players |
TABLE 21 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 22 Report Scope & Methodology Summary |
TABLE 23 Detailed Sources and Citations
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics – Drivers, Restraints, and Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend and Forecast, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Rate Trend, 2022–2035 (%) |
FIGURE 6 Market Share by Organ Type, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Application, 2025 vs 2035 (%) |
FIGURE 8 Market Share by End User, 2025 vs 2035 (%) |
FIGURE 9 Regional Market Share Distribution, 2025 (%) |
FIGURE 10 Regional Market Share Distribution, 2035 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 Competitive Landscape – Estimated Revenue Share Ranges, 2026 |
FIGURE 13 Vendor Positioning Matrix – Capability versus Regulatory Readiness |
FIGURE 14 Country-Level Growth Heat Map, 2026–2035

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Organ Type	Liver; Heart; Lung; Kidney; Intestine; Other Organ Types	Liver	Other Organ Types (Multi-Organ)
By Application	Drug Discovery and Lead Identification; Toxicology and Safety Assessment; Disease Modelling; Personalized Medicine; Other Applications	Drug Discovery and Lead Identification	Toxicology and Safety Assessment
By End User	Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Other End Users	Pharmaceutical and Biotechnology Companies	Contract Research Organizations
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Organ Type

Sub-Segment	Key Trend
Liver	Remains the default entry purchase; hepatotoxicity screening drives repeat consumable demand
Heart	Contractility and field-potential readouts align with existing proarrhythmia guidance
Lung	Air-liquid interface designs gain traction for inhaled biologics and respiratory infection work
Kidney	Proximal tubule models expand as transporter-mediated toxicity gains regulatory attention
Intestine	Absorption and microbiome co-culture applications broaden the addressable use case
Other Organ Types	Multi-organ and body-on-chip coupling moves the category toward systemic pharmacokinetics

Organ selection follows attrition risk rather than scientific elegance. Buyers start with the organ that kills the most candidates, then expand laterally once the workflow is embedded — which is why liver installations reliably precede everything else.

By Application

Sub-Segment	Key Trend
Drug Discovery and Lead Identification	Largest current spend; used for internal triage where evidentiary burden is lowest
Toxicology and Safety Assessment	Fastest expansion as regulatory qualification pathways formalise
Disease Modelling	Rare disease and oncology programmes drive bespoke device demand
Personalized Medicine	Patient-derived screening pilots await reimbursement clarity
Other Applications	Cosmetics, agrochemical, and government testing add non-pharmaceutical volume

Application mix is the leading indicator for this industry. When toxicology overtakes discovery in revenue terms — likely early in the 2030s — it will signal that chip data has moved from advisory to submission-grade.

By End User

Sub-Segment	Key Trend
Pharmaceutical and Biotechnology Companies	Dominant spender; adoption concentrated in safety and translational science functions
Academic and Research Institutes	Generate the peer-reviewed validation that unlocks industry procurement
Contract Research Organizations	Fastest growth; convert capital purchases into per-study operating expense
Other End Users	Chemical, cosmetics, and government laboratories diversify the demand base

The end-user picture explains why service revenue is scaling faster than hardware. Small and mid-sized biotechs cannot justify instrument capital, but they can approve a study invoice — and contract research organisations are built to capture exactly that demand.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”